目的 探讨缬沙坦胶囊联合醋酸泼尼松片治疗儿童原发性肾病综合征的临床疗效。方法 选取2016年7月—2017年7月在周口市中心医院接受治疗的原发性肾病综合征患儿120例为研究对象，采用随机数表法将入选的患儿分为对照组和治疗组，每组各60例。对照组口服醋酸泼尼松片，3片/次，3次/d，患儿的蛋白质转阴后，则更改为2片/次，1次/2 d。治疗组在对照组的基础上口服缬沙坦胶囊，患儿年龄<6.5岁：40 mg/次，患儿年龄≥6.5岁：80 mg/次，1次/d。两组患儿连续治疗8周。观察两组的临床疗效，比较两组的肾功能指标和血脂水平。结果 治疗后，对照组和治疗组的缓解率分别为75.0%、93.3%，两组比较差异有统计学意义（P<0.05）。治疗后，两组血浆白蛋白（Alb）水平显著升高，尿素氮（BUN）、24 h尿蛋白定量水平显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组肾功能指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组总胆固醇（TC）、尿肌酐（Cr）、三酰甘油（TG）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组血脂水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 缬沙坦胶囊联合醋酸泼尼松片治疗儿童原发性肾病综合征具有较好的临床疗效，能改善肾功能指标，降低血脂水平，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Valsartan Capsules combined with Prednisone Acetate Tablets in treatment of primary nephrotic syndrome in children. Methods Children (120 cases) with primary nephrotic syndrome in Zhoukou Central Hospital from July 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Prednisone Acetate Tablets, 3 tablets/time, three times daily. After proteinuria negative, dose was changed to 2 tablets/time, 1 times every 2 days. Children in the treatment group were po administered with Valsartan Capsules on the basis of the control group, age < 6.5 years:40 mg/time, age ≥ 6.5 years:80 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and renal function indexes and blood lipid levels in two groups were compared. Results After treatment, the remission rates in the control and treatment groups were 75.0% and 93.3%, respectively, and there was difference between two groups (P < 0.05). After treatment, Alb levels in two groups were significantly increased, but BUN and 24 h urine protein content levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And renal function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, TC, Cr and TG levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And blood lipid levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Valsartan combined with prednisone has clinical curative effect in treatment of primary nephrotic syndrome in children, can improve renal function indexes, and decrease blood lipid levels, with good safety, which has a certain clinical application value.